Effect of Apolipoprotein E Polymorphism on Serum Uric Acid Levels in Healthy Subjects

Background We have previously shown that apolipoprotein E (apo E-) polymorphism may affect serum creatinine concentration and predicted glomerular filtration rate in healthy individuals. On the other hand, there are limited data regarding the possible influence of apo E- polymorphism on serum uric acid (SUA) levels. Methods Two hundred ninety (148 male, 142 female) apparently healthy white individuals were studied. apo E- genotypes, serum lipid parameters including apolipoproteins, insulin resistance using the homeostasis model assessment (HOMA) as a marker, serum and urine creatinine levels, and serum and urine uric acid concentration were determined in all participants. Results The apo E-2 allele was associated with lower serum levels of total cholesterol, higher levels of triglycerides and apo E-, and increased serum creatinine concentration compared with the apo E-3 and apo E-4 alleles in our population. Furthermore, the apo E-2 allele was associated with higher SUA levels (321.3 ± 101.1 μmol/L [5.4 ± 1.7 mg/dL]) compared with the apo E-3 allele (261.8 ± 89.2 μmol/L [4.4 ± 1.5 mg/dL]; p = .012) and the apo E-4 allele (243.9 ± 65.4 μmol/L [4.1 ± 1.1 mg/dL]; p = .010), whereas the apo E-2 allele was associated with a nonsignificant decrease in the fractional renal excretion of uric acid (FEUA) compared with the apo E-3 and apo E-4 alleles (7.9 ± 2.2% vs 8.7 ± 4.2% vs 8.9 ± 5.1%, respectively; p = .53). These observations remained statistically significant when the effect of apo E- polymorphism on SUA levels was adjusted for gender, age, systolic and diastolic blood pressure, body mass index, serum creatinine, and triglyceride and apo E- levels, as well as for HOMA index and FEUA. Conclusions Our data provide evidence, for the first time, that the apo E-2 allele is independently associated with increased SUA levels in healthy individuals.

[1]  D. Mikhailidis,et al.  Metabolic Syndrome: Clinical Features Leading to Therapeutic Strategies , 2004 .

[2]  M. Elisaf,et al.  The influence of serum apolipoprotein E concentration and polymorphism on serum lipid parameters in hemodialysis patients. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  M. Elisaf,et al.  Influence of apolipoprotein E polymorphisms on serum creatinine levels and predicted glomerular filtration rate in healthy subjects. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  M. Elisaf,et al.  Alcohol intake, serum uric acid concentrations, and risk of gout , 2004, The Lancet.

[5]  M. Austin,et al.  Heritability of C‐Reactive Protein and Association with Apolipoprotein E Genotypes in Japanese Americans , 2004, Annals of human genetics.

[6]  M. Elisaf,et al.  Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  M. Elisaf,et al.  Apolipoprotein E polymorphism in northwestern Greece: frequency and effect on lipid parameters. , 2004, Annals of clinical and laboratory science.

[8]  S. Daskalopoulou,et al.  The impact of serum uric acid on cardiovascular outcomes in the LIFE study. , 2004, Kidney international.

[9]  M. Elisaf,et al.  Apolipoprotein E and renal disease. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  M. Elisaf,et al.  Could apolipoprotein E polymorphisms be hidden behind the relation between bone mineral density and atherosclerosis in hemodialysis patients? , 2003, Osteoporosis International.

[11]  K. Cianflone,et al.  ApoE phenotype influences plasma ASP in hyperapoB subjects. , 2003, Atherosclerosis.

[12]  Andrea Mari,et al.  Methods for clinical assessment of insulin sensitivity and β-cell function , 2003 .

[13]  F. Tinahones,et al.  The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates. , 2003, Rheumatology.

[14]  M. Elisaf,et al.  The Effects of the Addition of Micronised Fenofibrate on Uric Acid Metabolism in Patients Receiving Indapamide , 2002, Current medical research and opinion.

[15]  A. J. Maxwell,et al.  Uric acid is closely linked to vascular nitric oxide activity. Evidence for mechanism of association with cardiovascular disease. , 2001, Journal of the American College of Cardiology.

[16]  M. Elisaf,et al.  Evaluation of five methods for determining low-density lipoprotein cholesterol (LDL-C) in hemodialysis patients(1). , 2001, Clinical biochemistry.

[17]  L. Ruilope,et al.  Hyperuricemia and renal function , 2001, Current hypertension reports.

[18]  D. Singer,et al.  Apolipoprotein E isoform polymorphisms are not associated with insulin resistance: the Framingham Offspring Study. , 2000, Diabetes care.

[19]  M. Grazina,et al.  Influence of apolipoprotein E genotype on blood redox status of Alzheimer's disease patients. , 1999, International journal of molecular medicine.

[20]  P. Sánchez-Guijo,et al.  Dietary alterations in plasma very low density lipoprotein levels modify renal excretion of urates in hyperuricemic-hypertriglyceridemic patients. , 1997, The Journal of clinical endocrinology and metabolism.

[21]  A. Saeki,et al.  [Hyperuricemia and insulin resistance]. , 1996, Nihon rinsho. Japanese journal of clinical medicine.

[22]  F. Tinahones,et al.  Increased VLDL levels and diminished renal excretion of uric acid in hyperuricaemic-hypertriglyceridaemic patients. , 1995, British journal of rheumatology.

[23]  J. Dallongeville,et al.  Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. , 1992, Journal of lipid research.

[24]  G. Reaven,et al.  Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. , 1991, JAMA.

[25]  D. T. Vernier,et al.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.

[26]  Y. Matsuzawa,et al.  Relationship between hypertriglyceridemia and uric acid production in primary gout. , 1989, Metabolism: clinical and experimental.

[27]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[28]  C. Ehnholm,et al.  Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. , 1987, The Journal of clinical investigation.

[29]  G. Utermann,et al.  Apolipoprotein E polymorphism in health and disease. , 1987, American heart journal.

[30]  E. Collantes Estévez,et al.  Renal excretion of urate by hyperuricaemic-hyperlipidemic patients. , 1992, Clinical rheumatology.

[31]  R. Terkeltaub,et al.  Apolipoprotein (apo) E inhibits the capacity of monosodium urate crystals to stimulate neutrophils. Characterization of intraarticular apo E and demonstration of apo E binding to urate crystals in vivo. , 1991, The Journal of clinical investigation.

[32]  R. Gregg,et al.  The role of apolipoprotein E and lipoprotein receptors in modulating the in vivo metabolism of apolipoprotein B-containing lipoproteins in humans. , 1988, Clinical chemistry.

[33]  Brewer Hb,et al.  The role of apolipoprotein E and lipoprotein receptors in modulating the in vivo metabolism of apolipoprotein B-containing lipoproteins in humans. , 1988 .